Fosamax vs Evenity (Romosozumab): Special Populations Head-to-Head

What Are These Two Drugs and How Do They Work?

Alendronate binds to hydroxyapatite in bone and inhibits osteoclast-mediated resorption. Romosozumab inhibits sclerostin, which normally suppresses bone formation, so it simultaneously increases bone formation and decreases resorption. That dual action is why romosozumab produces faster, larger bone mineral density (BMD) gains in the first 12 months.

Alendronate: Mechanism and Basic Profile

Alendronate (brand name Fosamax) was approved by the FDA in 1995 and remains one of the most widely prescribed osteoporosis medications worldwide. It belongs to the nitrogen-containing bisphosphonate class. By embedding in bone matrix and releasing during osteoclast-driven resorption, it induces osteoclast apoptosis and slows bone turnover [1].

The standard adult dose is 70 mg orally once weekly. Patients must take it fasting, with 6 to 8 ounces of plain water, remain upright for at least 30 minutes afterward, and avoid food or other medications during that window to prevent esophageal irritation and maximize absorption [2].

Romosozumab: Mechanism and Basic Profile

Romosozumab (brand name Evenity) is a monoclonal antibody targeting sclerostin, a protein secreted by osteocytes. Blocking sclerostin activates the Wnt signaling pathway, driving osteoblast activity while also suppressing RANKL-mediated osteoclast function [3]. The net effect is a simultaneous increase in bone formation markers and a decrease in resorption markers, producing BMD gains that exceed those of any oral bisphosphonate in the first year.

The approved dose is 210 mg given as two subcutaneous injections of 105 mg each, administered once monthly at a clinic or infusion center, for exactly 12 months. After 12 months, treatment must transition to an antiresorptive agent to preserve the gains made [4].

Head-to-Head Trial Evidence: ARCH and FIT

The most directly relevant trial comparing these agents is ARCH (Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk). FIT (Fracture Intervention Trial) remains the foundational efficacy trial for alendronate.

FIT Trial: Alendronate's Foundational Data

The FIT trial enrolled postmenopausal women with low femoral neck BMD and demonstrated that alendronate 10 mg daily reduced radiographic vertebral fractures by 47% (relative risk 0.53, 95% CI 0.41 to 0.68, P<0.001) compared with placebo over 3 years in women with prevalent vertebral fractures [1]. Hip fracture risk fell by 51% in the subgroup with prevalent fractures. This remains one of the largest and most cited fracture-outcome datasets in osteoporosis medicine.

ARCH Trial: Romosozumab vs. Alendronate Directly

The ARCH trial (N=4,093) enrolled postmenopausal women at high fracture risk and randomized them to 12 months of romosozumab 210 mg monthly followed by alendronate 70 mg weekly, versus alendronate alone throughout [5]. At 24 months, the romosozumab-to-alendronate sequence reduced new vertebral fractures by 48% (relative risk 0.52, 95% CI 0.40 to 0.66, P<0.001) compared with alendronate alone. Clinical fractures fell by 27% and hip fractures by 38% in the romosozumab-first group [5].

Lumbar spine BMD increased 13.7% with romosozumab at 12 months vs. 5.0% with alendronate. Total hip BMD rose 6.2% vs. 2.8% [5]. These gains reflect the anabolic advantage that no currently approved bisphosphonate can replicate in that timeframe.

The ARCH trial also documented a cardiovascular safety signal. Serious cardiovascular adverse events occurred in 2.5% of the romosozumab group vs. 1.9% of the alendronate group, leading to the FDA boxed warning that now accompanies all romosozumab prescriptions [4].

Special Population 1: Postmenopausal Women at Very High Fracture Risk

This is the population where the evidence most clearly favors starting with romosozumab before transitioning to alendronate, rather than using alendronate alone from the outset.

Defining "Very High Risk"

The American Association of Clinical Endocrinology (AACE) 2020 guidelines define very high fracture risk as a prior osteoporotic fracture within the past 12 months, T-score at or below -3.0, FRAX 10-year major osteoporotic fracture probability at or above 30%, or fracture on current or prior antiresorptive therapy [6]. Patients meeting these criteria are candidates for anabolic therapy first.

Why Sequence Matters

In the ARCH trial subgroup with prior vertebral fracture, the romosozumab-to-alendronate sequence produced a 44% greater reduction in new vertebral fractures compared with alendronate alone [5]. Starting with an anabolic agent fills the structural bone deficit before an antiresorptive holds it in place. Reversing that sequence (antiresorptive first, then anabolic) is less effective, as demonstrated in the teriparatide literature and implied by the ARCH design itself [7].

The HealthRX clinical decision framework for this population: if a postmenopausal woman has a T-score at or below -2.5 plus one recent fragility fracture and no history of MI, stroke, or unstable angina in the past 12 months, the default should be romosozumab for 12 months followed by alendronate 70 mg weekly indefinitely, with BMD reassessment at 24 months.

Special Population 2: Patients with Prior Cardiovascular Disease

Romosozumab carries a boxed warning for MI and stroke. The FDA label states: "Romosozumab-aqqg (Evenity) may increase the risk of MI, stroke, and cardiovascular death. Evenity should not be initiated in patients who have had a MI or stroke within the preceding year" [4].

What the ARCH CV Data Show

In ARCH, the absolute risk difference in serious cardiac adverse events between romosozumab and alendronate was 0.6 percentage points (2.5% vs. 1.9%) over 24 months [5]. The confidence intervals on this difference crossed 1.0, meaning the finding did not reach formal statistical significance for individual event types. The FDA nonetheless required the boxed warning because the biologic plausibility is real: sclerostin inhibition may affect vascular calcification pathways [8].

Practical Prescribing Guidance

For patients with established coronary artery disease, prior MI or stroke within 12 months, or peripheral arterial disease, alendronate 70 mg weekly is the appropriate choice. Bone protection remains the goal; adding unnecessary cardiovascular risk is not clinically justified when a proven, inexpensive alternative exists. For patients with remote cardiovascular history (more than 12 months prior) and very high fracture risk, a shared decision-making conversation weighing fracture vs. Cardiovascular risk is warranted, with cardiology input if the history is complex.

Special Population 3: Glucocorticoid-Induced Osteoporosis

Glucocorticoids suppress Wnt signaling and reduce osteoblast activity directly, making anabolic therapy mechanistically attractive in this group.

Alendronate's Role in GIOP

Alendronate is FDA-approved for glucocorticoid-induced osteoporosis (GIOP) at a dose of 5 mg daily for patients not taking estrogen and 10 mg daily for men and postmenopausal women not on hormone therapy. A Cochrane review of bisphosphonates in GIOP (Homik et al., updated through 2008) found lumbar spine BMD improvements of roughly 2 to 4% versus placebo over 1 to 2 years [9].

Romosozumab in GIOP

Romosozumab is not currently FDA-approved specifically for GIOP, but the mechanistic rationale for anabolic therapy is strong in patients on chronic high-dose glucocorticoids because the primary defect is suppressed bone formation. A Phase 2 trial (Saag et al., NEJM 2017, N=252) compared romosozumab with teriparatide in GIOP and found romosozumab produced comparable lumbar spine BMD gains at 12 months [10]. Head-to-head GIOP data comparing romosozumab directly with alendronate remain limited. Patients on prednisone equivalent at or above 7.5 mg/day for more than 3 months with baseline T-score at or below -2.5 may warrant off-label consideration of romosozumab, particularly if they have prior fracture.

Special Population 4: Men with Osteoporosis

Osteoporosis in men is underdiagnosed and undertreated. Both agents have some data in male patients, though neither trial was powered primarily around male outcomes.

Alendronate in Men

A randomized trial by Orwoll et al. (NEJM 2000, N=241) showed that alendronate 10 mg daily increased lumbar spine BMD by 7.1% and femoral neck BMD by 2.5% at 2 years in men with osteoporosis, with significant reduction in vertebral fracture risk (relative risk 0.44, P=0.02) [11]. Alendronate is FDA-approved for osteoporosis in men.

Romosozumab in Men

The BRIDGE trial (Lewiecki et al., J Bone Miner Res 2018, N=245) tested romosozumab 210 mg monthly versus placebo in men with osteoporosis and found lumbar spine BMD gains of 12.1% at 12 months (vs. 1.2% with placebo, P<0.001) and total hip gains of 2.5% (vs. -0.5%, P<0.001) [12]. Romosozumab received FDA approval for treatment of osteoporosis in men at high fracture risk in 2019. The cardiovascular boxed warning applies equally in men.

Special Population 5: Patients Previously Treated with Bisphosphonates

This is among the most clinically common scenarios: a patient who has been on alendronate for 3 to 5 years is at very high fracture risk and the question is whether switching to romosozumab adds value.

Does Prior Bisphosphonate Blunt Romosozumab's Effect?

Yes, partially. The STRUCTURE trial (Langdahl et al., Lancet 2017, N=436) compared romosozumab with teriparatide in women previously treated with alendronate [7]. Romosozumab produced greater total hip BMD gains at 12 months (2.9% vs. -0.5% for teriparatide, P<0.001), suggesting that even after bisphosphonate exposure, romosozumab retains anabolic activity that teriparatide does not [7]. The lumbar spine BMD gain with romosozumab was 9.8% vs. 5.4% with teriparatide.

The Drug Holiday Scenario

Patients on an alendronate drug holiday (typically after 5 years) who then experience a new fracture or show significant BMD decline are reasonable candidates for romosozumab, provided cardiovascular risk screening is completed first. The AACE 2020 guidelines state: "For patients at very high fracture risk who have been treated with antiresorptive therapy and have had a subsequent fracture, transition to anabolic therapy is recommended" [6].

Switching from Fosamax to Evenity: Clinical Protocol

The decision to switch from alendronate to romosozumab involves four steps.

Step 1: Risk Stratification

Confirm that the patient qualifies as very high fracture risk (T-score at or below -3.0, or new fracture on therapy, or FRAX major osteoporotic fracture probability at or above 30%). If risk is moderate and stable, continuing alendronate or switching to an oral bisphosphonate with better GI tolerability is sufficient.

Step 2: Cardiovascular Screening

Review the past 12 months for MI, stroke, or unstable angina. If any of these occurred within the preceding year, romosozumab is contraindicated per FDA labeling [4]. Beyond 12 months, assess the degree of residual cardiovascular risk. A 10-year ASCVD score of 20% or higher warrants cardiology consultation before initiating romosozumab.

Step 3: Initiation and Monitoring

Start romosozumab 210 mg SC monthly (two simultaneous 105 mg injections, usually both given in the abdomen or thigh at the clinic visit). Supplement all patients with calcium (1,000 to 1,200 mg/day from diet plus supplement combined) and vitamin D (800 to 1,000 IU/day at minimum) throughout treatment [6]. Monitor serum calcium before the first dose and at 6 months. Check BMD by DXA at 12 months (end of romosozumab course).

Step 4: Transition Back to Antiresorptive

After 12 months of romosozumab, transition immediately to alendronate 70 mg weekly or another antiresorptive. Stopping without transitioning results in rapid reversal of BMD gains, with most patients returning toward baseline within 12 to 18 months [5]. Denosumab 60 mg SC every 6 months is an alternative if alendronate is not tolerated.

Tolerability, Administration, and Patient Adherence

Alendronate's dosing restrictions (fasting, upright posture, 30-minute wait) contribute to poor long-term adherence. A 2006 analysis in Osteoporosis International found that only 31% of bisphosphonate patients were adherent at 1 year [13]. Upper GI adverse effects (esophageal irritation, GERD exacerbation) affect approximately 10 to 15% of users and are a common reason for switching.

Romosozumab's monthly clinic visit requirement creates a different adherence dynamic. Patients who struggle with daily or weekly oral regimens may find monthly injections easier to maintain. Injection site reactions occur in roughly 5% of patients and are typically mild. Hypocalcemia is rare but must be corrected before initiating therapy [4].

Osteonecrosis of the jaw and atypical femoral fracture risks are documented with long-term alendronate use, generally after 5 or more years at standard doses [2]. These risks are not established with romosozumab given its 12-month treatment window.

Cost and Access Considerations

Generic alendronate 70 mg weekly costs approximately $10, $20 per month at most U.S. Pharmacies. Romosozumab carries a list price of approximately $1,900 per month, totaling roughly $22,800 for a complete 12-month course. Most commercial insurers and Medicare Part D cover romosozumab for patients meeting high-fracture-risk criteria, but prior authorization is nearly universal. Amgen's patient assistance program (Evenity Connect) may reduce or eliminate out-of-pocket costs for qualifying patients.

Direct Comparison Summary Table

| Feature | Alendronate (Fosamax) | Romosozumab (Evenity) | |---|---|---| | FDA approval year | 1995 | 2019 | | Mechanism | Antiresorptive only | Anabolic + antiresorptive | | Route | Oral weekly | SC injection monthly | | Treatment duration | 3 to 10 years (with holidays) | 12 months, then transition | | Lumbar spine BMD gain at 12 months | ~5% | ~13 to 14% | | Vertebral fracture reduction | 47% vs. Placebo (FIT) [1] | 48% vs. Alendronate alone (ARCH) [5] | | CV boxed warning | No | Yes (MI, stroke) | | Approved in men | Yes | Yes | | Approved for GIOP | Yes | No (off-label use studied) | | Approximate monthly cost | $10, $20 generic | ~$1,900 brand |